A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the effectiveness of lurasidone as maintenance treatment for schizophrenia. Method: Adults experiencing an acute exacerbation of schizophrenia initially received 12–24 weeks of open-label treatment with lurasidone (40–80 mg/d, flexibly dosed). Patients who maintained clinical stability for ⩾12 weeks were randomized in double-blind fashion to placebo or lurasidone (40–80 mg/d, flexibly dosed) for an additional 28-week treatment period. The primary efficacy endpoint was time to relapse (based on Kaplan–Meier survival analysis). Results: A total of 676 patients enrolled in the open-label phase; 285 met protocol-specified stabilization criteria and were randomized to lurasidone ( N=144) or placebo ( N=141). During the open-label phase, mean Positive and Negative Syndrome Scale total score decreased from 90.1 to 54.4 in patients who met clinical stability criteria and were randomized. In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447–0.983); p=0.041). Probability of relapse at the double-blind week 28 endpoint (based on Kaplan–Meier analysis) was 42.2% in the lurasidone group and 51.2% in the placebo group. Minimal changes in weight, lipid, glucose, and prolactin were observed throughout the study. Conclusions: This multicenter, placebo-controlled, randomized withdrawal study demonstrated the efficacy of lurasidone for the maintenance treatment of patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 3×
“…Angus, 1970), the Barnes Akathisia Rating Scale (BARS) (Barnes, 1989), and the Abnormal Involuntary Movement Scale (AIMS) (Guy, 1976)), suicidal ideation (using the Columbia–Suicide Severity Rating Scale (C-SSRS) (Posner et al., 2011)), laboratory measures, vital signs, and electrocardiogram (ECG).”
MethodLeucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“A meta-analysis of randomized, controlled trials of 15 antipsychotic agents in the treatment of patients with schizophrenia found relatively small differences between medications in terms of efficacy, but substantial differences in side effects (Leucht et al., 2013).”
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 3×
“(Leucht et al., 2012).”
ResultInfluentialCsernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
Cited by
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Ward, K., & Citrome, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s169369 · Cited by 181
“They used data from the brexpiprazole relapse-prevention study(8) and two similarly designed trials utilizing cariparazine(26) and lurasidone.(27) Primary outcomes were cost per relapse avoided and hospitalization avoided.”
Fleischhacker, W. W., Hobart, M., Ouyang, J., Forbes, A., Pfister, S., McQuade, R. D., Carson, W. H., Sanchez, R., Nyilas, M., & Weiller, E. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw076 · Cited by 88
“1% (Tandon et al., 2014); oral paliperidone extended-release 25.”
Récalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38
Aigbogun, M. S., Liu, S., Kamat, S. A., Sapin, C., Duhig, A. M., & Citrome, L. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s160252 · Cited by 18
“Key clinical inputs were derived from 52-week maintenance relapse studies for brexpiprazole 17 and cariprazine, 20 a 28-week maintenance relapse study for lurasidone, 21 and published reports and package inserts (PIs) for SGAs used for composite therapy.”
Influential
Metadata
- Authors
- Tandon, R., Cucchiaro, J., Phillips, D., Hernandez, D., Mao, Y., Pikalov, A., & Loebel, A.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-12-08
- Volume
- 30
- Issue
- 1
- Pages
- 69-77
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2274260754
- Cited by
- 57
- References
- 4
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. https://app.cochat.ai/papers/10.1177/0269881115620460
- The paper
- Tandon, R., Cucchiaro, J., Phillips, D., Hernandez, D., Mao, Y., Pikalov, A., & Loebel, A. (2016). A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology. https://doi.org/10.1177/0269881115620460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.